Al Sandrock, Voyager Therapeutics CEO

Voy­ager goes big, se­cur­ing mul­ti-bil­lion dol­lar gene ther­a­py de­vel­op­ment deal with Neu­ro­crine

The neu­ro­log­i­cal dis­ease out­fit helmed by Bio­gen’s for­mer R&D chief an­nounced a big gene ther­a­py deal Mon­day, start­ing #JPM23 with its largest deal to date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.